[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100545987":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":22,"interventions":31,"overallOfficials":36,"centralContacts":41,"locations":47,"responsibleParty":64,"collaborators":13,"id":66,"slug":13,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":13,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":73,"minAge":74,"maxAge":13,"enrollmentInfo":75,"targetDuration":13,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":13,"overallStatus":49,"whyStopped":13,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Sciton","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Histological clearance","Efficacy of the treatment is determined by histological changes measured at 16 weeks post final treatment","16 weeks",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":20},"SINGLE",[21],"PARTICIPANT",[23,28],{"label":24,"type":25,"description":13,"interventionNames":26},"Treatment + PRP Arm","ACTIVE_COMPARATOR",[27],"Device: Fractional 2940 nm Laser",{"label":29,"type":25,"description":13,"interventionNames":30},"Treatment only Arm",[27],[32],{"type":33,"name":34,"description":34,"armGroupLabels":35,"otherNames":13},"DEVICE","Fractional 2940 nm Laser",[24,29],[37],{"name":38,"affiliation":39,"role":40},"Josee Parent, MD","Clinique Medicale Uro-Gyneco de l'Abitibi","PRINCIPAL_INVESTIGATOR",[42],{"name":43,"role":44,"phone":45,"phoneExt":13,"email":46},"J Patel","CONTACT","6504939155","clinicaltrials@sciton.com",[48],{"facility":39,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"RECRUITING","Val-d'Or","Quebec","J9P1W1","Canada","CA",{"type":56,"coordinates":57},"Point",[58,59],-77.79737,48.0974,{"lat":59,"lon":58},[62],{"name":38,"role":44,"phone":63,"phoneExt":13,"email":13},"819-825-3800",{"type":65,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100545987",false,"NCT06389071","Laser Treatment for Lichen Sclerosus","Safety and Efficacy of Ablative Fractional 2940 nm Laser Treatment for Lichen Sclerosus Lesion","Inclusion Criteria:\n\n* Female aged 18 years or older\n* Biopsy-proven vulvar lichen sclerosus lesion\n* Experiencing one or more of the following symptoms of LS:\n\n  1. Dryness\n  2. Itching\n  3. Burning\n  4. Bleeding\n  5. Blistering\n  6. Soreness\n  7. Easily bruises\n  8. Easily tears\n  9. Ulcerated lesions\n  10. Painful intercourse\n* Negative urine pregnancy test if subject is of childbearing potential before enrollment\n* Absence of vulvovaginal infection i.e. fungi, bacterial vaginosis, and STI\n* Ability to understand and sign informed consent, questionnaires, and all investigation requirements\n* Willing to consent to clinical photographs of the treatment area\n* Willing to consent to ultrasound images of the treatment area\n* Willing and able to logistically follow schedule of treatments and follow-up visits\n\nExclusion Criteria:\n\n* Pregnancy, less than 3 months postpartum, or planning to become pregnant during the investigation to protect integrity of the data\n* Is a nursing mother\n* History of uncontrolled malignant disease\n* Active urogenital infection or chronic infection (i.e., candida, herpes, herpes simplex, bacterial vaginosis, trichomoniasis, or other infection)\n* Immunocompromised (e.g., lymphoma, AIDS, Wiskott-Aldrich syndrome)\n* Subjects with genital skin disease, psoriasis due to risk of koeberizing\n* Subjects on immunosuppressants: mycophenolate, retinoids, azathioprine, cyclosporin\n* Known allergy or intolerance to local anesthesia\n* Known history of connective tissue disease\n* Known propensity for keloid formations\n* Known medical condition that may affect wound healing\n* Any reason that the investigator deems prohibits participation in the investigation",true,"FEMALE","18 Years",{"count":76,"type":77},50,"ESTIMATED","INTERVENTIONAL",[80],"NA","Fractional ablative laser treatment for Lichen Sclerosus lesion",[83],"Lichen Sclerosus Lesion","2026-04-21",{"date":86,"type":87},"2026-04-23","ACTUAL",{"date":89,"type":87},"2024-03-01",{"date":91,"type":77},"2027-12-30",{"name":5,"class":6},1]